Brought to you by 
Biscayne NeuroTherapeutics spins out of Biscayne Pharmaceuticals, raises $3mm Series B round
02 Feb 2017
Executive Summary
Biscayne Pharmaceuticals Inc. is spinning out Biscayne NeuroTherapeutics Inc. (BNT) to advance the former's Phase I epilepsy compound BIS001. BNT concurrently completed a $3mm Series B round co-led by Quark Venture and GF Securities, which together invested $1.6mm through the Global Health Sciences Fund; each also added a member to the new company's board. Mesa Verde Venture Partners, other existing Biscayne Pharmaceuticals backers, and new private investors also participated.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
-
Molecular Diversity
- Natural Products
-
Molecular Diversity
-
Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Financing
- Spin-Off
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biscayne NeuroTherapeutics spins out of Biscayne Pharmaceuticals, raises $3mm Series B round
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice